Akebia heads into its third-quarter report with a story that is improving underneath and shrinking on the surface. Its anemia drug Vafseo (VAFSIO) just posted its best quarter yet, and an early, positive interim readout from the VOICE trial handed management fresh ammunition in its push to make the drug a standard of care in dialysis. Yet the stock has slid about 15% since that report, lagging the S&P 500 by roughly 15.5 percentage points. The November 5 release, due before the open, needs to show whether the clinical win is turning into prescriptions fast enough to offset a fading legacy franchise and a known pricing cliff in 2027.

The Street is bracing for contraction. Consensus calls for revenue of $46.9 million, down about 20% from $58.8 million a year ago and slightly below the $49.1 million reported last quarter. The expected loss is 3 cents a share, a touch wider than the 2-cent loss in the second quarter and well below the breakeven result of a year earlier. Management has not issued formal financial guidance. That leaves the consensus reflecting the math of two opposing products more than any company target. Auryxia (Arixia), the phosphate binder that once carried the business, fell to $25.5 million last quarter from $47.2 million a year earlier as generic competition widened. A modest sequential revenue dip implies analysts expect Vafseo growth to cover only part of that continuing slide.

Vafseo's trajectory is the heart of the quarter. Net sales jumped 34% sequentially to $21.3 million in the second quarter, patients on therapy climbed past 10,500 from about 7,500, and the prescriber base grew roughly 17%, with about a third now outside USRC, the early anchor customer. Refill adherence held near 89%. The bull case requires another clear step up in patients and prescribers, along with signs that DaVita's village-wide observed-dosing protocol, rolled out in early June, is producing a full quarter of volume. Engagement at DaVita and other large dialysis organizations reached the operational level after VOICE, so this is the first report that can show whether that attention is turning into orders. A Vafseo number that stalls near $21 million would challenge the standard-of-care narrative. One that clears the high $20 millions would suggest the launch is accelerating.

There are complications. The VOICE data, which showed a 10% reduction in hospitalizations versus an ESA comparator, had not yet been published or presented, which limits what the sales force can promote. Updates on presentation timing matter. So does any further detail on the 2027 reset. Management has already said Vafseo revenue will fall next year despite higher volume, because pricing drops to ESA levels once the TdAPA add-on payment period expires at the end of 2026. Investors will want a sense of how deep that cut is and how much volume growth is needed to bridge it.

The balance sheet is also under scrutiny. Cash slipped to $155.5 million from $162.6 million, the company took a $1.9 million charge to streamline its commercial team, and a refinancing of its senior secured term loan is planned. Progress on that deal, along with operating expense discipline, will shape how comfortable the market feels about the path to profitability. Pipeline items, including the newly started Phase II basket trial of abribifus, are longer-dated and unlikely to move the stock this quarter.

Sentiment has cooled. It is now 7.7% bearish versus 2.0% bearish ahead of the last report. At 76 cents, the stock sits well below its 200-day average of $1.15 and in the lower half of its post-earnings range of 54 cents to $1.05, which is a step down from the prior quarter's $0.82 to $1.46 band. Expectations are subdued, but the bar is specific. Akebia needs to prove that Vafseo's patient growth is compounding fast enough to outrun both Auryxia's decline and next year's price reset. A strong volume print would support last quarter's confident tone, while a plateau would suggest VOICE has not yet changed prescribing behavior.